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or those seeking exposure to 
pure science, there are many 
reasons not to attend the circus 
that is the biennial AIDS conference. 
Some distractions are at least entertaining: 
Buddhist monks looking lost; a self-
declared Prince from Nigeria; a posse of 
African grannies sponsored by Stephen 
Lewis (the UN special envoy for AIDS 
in Africa); and a fashion exhibit of 
dresses made entirely of condoms. 
Others—such as the four-hour wait to 
register, self-serving speeches by min-
isters of health, activists popping up on 
stage like yo-yos, and Clinton-related 
mobs—are more irritating.
Yet researchers willing to embrace 
the event in all its craziness are exposed 
to a richness of experience—and an inter-
twining of science and society—that 
cannot be had at any other science-related 
conference. “For basic science, I couldn’t 
say it’s better than going to a focused 
meeting,” says Michael Tremblay (McGill 
University, Montreal, Canada). “But here 
it’s important because the entire planet is 
talking about HIV/AIDS.”
The evolution of a conference
In the last 25 years, 25 million people 
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have died of AIDS, and approximately 40 
million now live with HIV. Every day, an 
estimated 11,200 people are infected and 
8,000 die. Although 1.65 million people are 
now receiving antiretroviral treatment, 70% 
of those in need still lack drugs. The epi-
demics that are most out of control are 
among intravenous drug users (especially 
in Eurasia), men who have sex with men 
(everywhere), and the generalized epidemic 
in sub-Saharan Africa.
The AIDS meeting is one response 
to this epidemic. From its humble begin-
nings in 1985 as a small scientifi  c gath-
ering, the conference has grown to a 
complex mixture of  24,000 participants, 
including basic scientists, clinicians, epi-
demiologists, behavioral scientists, politi-
cians, activists, and many who implement 
prevention and treatment programs in 
both developed and developing countries. 
Also present are 3,000 journalists from 
over 100 countries (see Should journalists 
question science?). At any one time there 
can be 12 concurrent sessions, offi  cial 
press conferences (three per hour, every 
hour), “global village” events put on by 
nongovernmental organizations (NGOs), 
and activist events.
The activists in particular can get 
creative. The threat of protests kept repre-
sentatives of the drug company Abbott 
from manning (or even constructing) their 
intended booth at the conference. Activ-
ists were more than happy to take over the 
prime real estate, with a banner declaring 
“Abbott: Your booth is as empty as your 
promises.” The group was protesting 
Abbott’s pricing policy for Kaletra 
(lopinavir/ritonavir), a two-in-one, once-
a-day pill that can be stored at room tem-
perature and is thus perfect for developing 
country conditions.
Less raucous groups tried to get at-
tention by forming Global Coalitions for 
Just About Anything You Can Imagine. 
(Right now, someone is preparing a 
PowerPoint slide in which they incorporate 
GCJAAYCI, which they will use happily 
without explaining what the acronym 
stands for. The only people who like jar-
gon more than scientists are, it turns out, 
international policy professionals.) These 
groups vie with each other for more atten-
tion using seminars, press conferences, 
voluminous reports, and declarations.
This circus-like atmosphere was one 
Dutiful applause breaks out regularly at AIDS conferences in response to expected 
platitudes. But the applause for Gita Ramjee’s concluding statement was both heart-
felt and hopeful. Ramjee (South African Medical Research Council, Durban, South 
Africa) was part of a session on HIV prevention, a ﬁ  eld in which the mantra has 
been ABC for abstinence, be faithful, and use condoms. It has not been enough.
Fortunately, said Ramjee, there are other hopes on the horizon. “I would like 
to believe that HIV prevention soon will be more than ABC,” she said. “We will 
add one more C for circumcision. We will add D for diaphragm, E for exposure 
prophylaxis, F for female-controlled options [such as microbicides], G for genital 
tract infections, H for HSV-2 suppression, and I for immunity, using vaccines.”
Cue the applause. The focus came back on prevention for this conference 
because, as Kevin De Cock (director of 
the World Health Organization’s 
Department of HIV/AIDS) said, “We 
can’t treat our way out of this epidemic. 
We need to use our treatment successes 
to enhance prevention.” And ABC has 
fallen short, said Cristina Pimenta 
(executive director of the Brazilian Interdisciplinary AIDS Association), because 
these approaches rely on “pure, individual responsibility” in an environment where 
vulnerability is “a product of social and economic exclusion.” This is especially true 
for women, who need prevention methods that are under their own control.
The “I” in Ramjee’s list is arguably most distant (see The ultimate hope), but 
there was encouraging news about many other prevention approaches. In one 
South African trial, circumcision reduced the risk of HIV infection by 60%. Also 
promising is the reported safety of using a single AIDS drug called tenofovir as 
a possible daily prophylactic. Efﬁ  cacy is yet to be shown for this approach, 
because the education efforts in the ﬁ  rst trial were so successful that they 
reduced new infections in both the treatment and control arms. Results are 
expected in 2007 for trials investigating the efﬁ  cacy of diaphragms, HSV2 
suppression, and so-called ﬁ  rst generation microbicides.
The greatest hope is being put on microbicides, either applied directly or via 
long-acting vaginal rings. The ﬁ  rst generation agents are primarily polymers that 
block surface attachment of viruses, but there is greater excitement about gel 
formulations of antiretroviral drugs. John Moore (Weill Medical College of Cornell 
University, New York, NY) has shown 
signiﬁ  cant protection with microbicides in 
macaque trials, even when the monkeys 
were challenged several hours after 
microbicide application. Eventually, he 
said, the right mix of antiviral agents will 
emerge for microbicides as it did for 
systemic treatment of AIDS. “The case for 
combination microbicides, in my view, 
is absolutely obvious and almost 
inarguable,” he said.
Pimenta sounded a note of caution, 
however, regarding “the present tendency 
to see biomedical interventions as quick 
technological, magical solutions to HIV/
AIDS prevention.” As with antiretroviral 
treatment, getting any given technology 
to the masses will be perhaps the greatest 
challenge of all, especially when the tar-
get audience is all of humanity.
Strike a pose.  Condom dresses designed 
by Brazilian Adriana Bertini were a sensation, 
but getting people to use condoms for HIV 
protection remains a challenge.
“SEX NICE, 
but de AIDS ting…”
[from a T-shirt worn by a delegate from 
Montserrat, a tiny Caribbean nation]
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The Bill effect.  Billionaire philanthropist Bill Gates and ex-President Bill Clinton both drew attention 
to new prevention technologies (left), and increased the general level of chaos (right).
which is to address policy and social sci-
ences in the fi  eld. It is not regarded as a 
scientifi  c or clinical meeting any more.”
Even some of the researchers who 
attended agreed with this statement. Kelly 
MacDonald (University of Toronto, 
Canada) points out that the largest num-
ber of basic researchers are based in the 
United States, and yet the AIDS confer-
ence is never held in the US because US 
immigration policies restrict entry of 
HIV-positive individuals. That makes any 
AIDS meeting an expensive international 
meeting for US researchers. Adding that 
factor to all the others, she says, “This is 
dying as a basic science meeting.”
And yet…
It is certainly easy, with policy posturing 
getting more of the headlines than science, 
for the conference to be maligned. The local 
Toronto Star newspaper welcomed delegates 
with a cover story about the “AIDSerati” 
(Bill Clinton, Bill Gates, and friends), and 
then featured a piece by right-wing think-
tanker Michael Fumento. According to 
Fumento’s fi  nely reasoned article, the whole 
thing is overblown. After all, a very early 
prediction of 50 million AIDS deaths in 
Africa by 2005 had never come to pass—it 
turned out to be only 20 million. Perhaps 
this is why Canadian Prime Minister 
Stephen Harper declined the conference 
invitation, choosing instead to tour a mili-
tary base north of the Arctic Circle.
But as the Toronto Star and the rest 
so have the 
researchers left 
Just as the
 politicians 
have come, 
reason that the International AIDS Society 
(IAS) created a second conference: the 
IAS Conference on HIV Pathogenesis, 
Treatment, and Prevention. This science- 
and clinical-only event is now held in odd 
years (the fourth will be next year in 
Sydney, Australia), whereas the original all-
inclusive AIDS conference is held in the 
even years. The latter conference remains 
unique, as only here does science meet 
  policy. Basic science is needed at both con-
ferences, said IAS president Pedro Cahn, 
because it progresses more rapidly than the 
social science and fi  eld implementation.
But the adoption of a research-only 
conference may have accelerated the exo-
dus of basic science from the original 
AIDS conference. Even outside of confer-
ences, HIV scientists are constantly bom-
barded by interview and public speaking 
requests, and the opportunity to escape 
from the policy babble has been irresist-
ible for some. By the 2004 Bangkok AIDS 
meeting, the reporter Laurie Garrett was 
declaring in the New York Times that the 
conference content was “the worst science 
ever presented at an AIDS meeting” with 
“top HIV laboratory researchers…fi  nding 
it irrelevant.” David Ho, director of the 
Aaron Diamond AIDS Research Center 
(New York, NY) chose not to attend this 
year because of the “general lack of new 
science” and a vaccine meeting occurring 
soon afterwards. “True or not,” he said by 
email, “the general perception is that the 
meeting now serves a different purpose, 
of us observed the conference in action, it 
was hard not to be inspired, and on several 
levels. First, there was the fascinating 
assortment process by which issues and 
agendas were prioritized. The most obvi-
ous case of this prioritization was the con-
sensus on the number one message from 
the conference. Like a jealous gaggle of 
fashion designers who somehow all end 
up showing aubergine-colored outfi  ts for 
their Spring collection, the 24,000 partici-
pants interpreted this conference’s generic 
offi  cial theme of “Time to Deliver” as 
requiring a renewed emphasis on preven-
tion and new prevention technologies (see 
The ABCDEFGHI of prevention).
This process is not only intriguing 
in its own right but clearly relevant for 
the researcher wondering where the fund-
ing tides will turn to next. Is his or her 
general area now the hit of the year, and, 
if not, why not? Policy debates also ad-
dress more nuanced questions, such as 
which drug classes are most in need of 
further research, based on feedback from 
the fi  eld on resistance, prices, licensing 
diffi  culties, or dosing diffi  culties.
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shift from in vitro to patient studies, 
many of which are based in developing 
countries where NGOs may be impor-
tant actors in the healthcare system. The 
early years of HIV research were concen-
trated on understanding the actions of 
individual HIV genes as revealed by in 
vitro assays. The newer research is focused 
on the immunological response to the virus. 
It was not always clear whether the confer-
ence was helping funnel community con-
cerns from the fi  eld to those carrying out 
these studies in developing countries (see 
Science on safari), but at least the potential 
for interaction was there.
The connections to policy debates 
may be more obvious for clinical re-
searchers, but there are other benefi  ts for 
basic researchers. The conference gives 
everyone license to think not just about 
details of data but also more broadly about 
strategy. “It’s getting so focused doing 
basic science,” says Tremblay. “When you 
are always working in the same strain…
maybe you are missing something.”
Keeping them honest
The presence of activists and scientists in 
one place results in a dialogue that “is 
Science on safari
Forget the occasional PCR machine sent to a random African 
country. Finally, with AIDS, real scientiﬁ  c alliances are being 
formed between research efforts in developed and develop-
ing countries.
Studies require numbers. The efﬁ  cacy of a prevention 
technology can only be shown by contrasting the treatment arm 
with a control arm in which there are many new infections. 
The bulk of those new infections are in developing coun-
tries and so the bulk of the research is there too. It is from the 
developing world that we are seeing results on preexposure 
prophylaxis, vaccines, microbicides, and prevention of mother-
to-child transmission.
There are many beneﬁ   ts from these collaborations. 
Researchers from developing nations have a greater presence 
at the AIDS conference than at probably any other major scien-
tiﬁ  c meeting. And the prevention trials are happening in coun-
tries that need the successful products most. “What we are mea-
suring is not efﬁ  cacy but effectiveness—with the real constraints” 
of incomplete compliance in community settings, said Quarraisha 
Abdool Karim (Columbia University, New York, NY).
But clinical research does not translate seamlessly to a 
new location. In early trials, detailed investigations showed that 
“there was no way that placebo was understood,” said Charles 
van der Horst (University of North Carolina, Chapel Hill, NC). 
very helpful both ways,” said Sharon 
Lewin (Monash University, Melbourne, 
Australia). “Basic scientists need to know 
what is important globally. What we prob-
ably don’t do well is to make [scientists 
and activists] intelligible to each other.”
Ideally, those who wander into the 
universe of basic science can bring a 
refreshing change in perspective. One re-
searcher presented a study on virus entry 
into (and inactivation by) oral epithelial 
cells. It was a nice piece of science but 
somewhat shrouded in talk of mono-
layer cultures and markers of transcytosis 
  pathways. Then came the questions—most 
from scientists and some from nonscientists. 
An audience member who appeared to fall 
into the latter camp asked, “What happens 
when you add virus-infected breast milk?” 
The researcher seemed amused by the na-
ïveté of the question. But the facts in the 
fi  eld are simple: we know that HIV does 
not appreciably infect via the oral route 
except in babies receiving infected breast 
milk. In this context, the simple question 
was the only relevant question.
Other questioners were more direct. 
After a presentation by a student whose 
ample enthusiasm was not matched by his 
He’s seen it before.  Anthony Fauci, director of 
the US National Institute of Allergy and Infectious 
Diseases, waits out a protest.
The emphasis on new prevention 
technologies has also resulted in stronger 
connections between researchers and fi  eld 
workers, as the researchers rely on the 
fi  eld workers to explain how communica-
tion strategies can be best used in preven-
tion campaigns to increase compliance. 
“There is a new engagement, and I think it 
is very encouraging,” said David Cooper 
(University of New South Wales, Sydney, 
Australia). “It’s very different from 
clinical trials where the science of clinical 
trials was well-known before HIV.”
Interaction is also fostered by the 
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With pictures and practice, “I think it is possible to get informed 
consent,” he said, “but you have to work hard at it.”
Other challenges come from the trial designs being too 
successful. Ethics require all prevention researchers to give 
those in both treatment and placebo arms the best in preven-
tion counseling. As a result, “across almost all prevention 
trials… the incidence rates drop dramatically,” said Karim. 
“So we have to do much bigger trials.” If more prevention 
technologies are approved for use, this “problem” will only 
increase for future prevention and vaccine trials.
The need to integrate different prevention methods is clear, 
said Renee Ridzon of the Bill and Melinda Gates Foundation. 
“None of the prevention methods will be 100% effective,” she 
said. “They all need to be used in the context of other preven-
tion methods.” That will increase the concern about risk com-
pensation—the increase in one unsafe behavior (e.g., sex with-
out a condom) in the mistaken belief that another prevention 
method (e.g., tenofovir prophylaxis) will take care of all risk. 
This concern holds for all prevention methods, but the criticism 
has been leveled primarily at those doing the tenofovir pre-
exposure prophylaxis (PrEP) trials. “I think it’s highly unfortunate 
that PrEP has been singled out,” said Joep Lange (University of 
Amsterdam, Netherlands). Microbicide and vaccine trials are 
not held up to same standard, he said, probably because the 
backgrounds of most AIDS activists are in drug treatment.SPECIAL REPORT | The Journal of Experimental Medicine  2399
clarity, an audience member observed: 
“You mentioned several times that this was 
very exciting. Why?” For Killian O’Brien 
of AIDS Calgary (a service organization), 
his impatience with impenetrable science 
in a vaccine session was phrased more 
  urgently. “I’m sure all this science stuff is 
very important,” he said, shaking with 
  nervousness. “But I’d like something to 
bring back to my clients. Sometimes we 
need straight English.”
Some jargon will always be needed 
to communicate ideas that are buried deeply 
in a complex technological landscape of 
ideas. But that jargon need not preclude 
understanding by others. The AIDS con-
ference featured perhaps the most science-
literate nonscientists in the world—activists 
who tossed around names of cytokines and 
cell surface markers without a second 
thought. In O’Brien’s defense, I was com-
pletely stumped by most of the talks in the 
session that prompted his comment.
“We adopt jargon far too much,” 
agreed Kelly MacDonald, who chaired 
the symposium in question. With fewer 
big name scientists attending, the talks are 
often left to students, and many of them 
had clearly had insuffi  cient guidance from 
their supervisors. “The [conference orga-
nizers] have set up for people to get tips 
on presentation… but the uptake has been 
very low,” said MacDonald. “We’re mak-
ing this fi  eld completely inaccessible.”
Restoring that access is vital both for 
the HIV/AIDS community and for the re-
search community in general. Marilyn 
Chase of the Wall Street Journal captured 
very well the unique nature and social im-
pact of what is now undeniably an HIV/
AIDS industry:
“AIDS has, in a way, changed 
everything. It’s changed the way we 
look at disease and its spread. It’s 
changed the way we look at research, 
how research is conducted, how we 
share the fruits of that research with 
the people who volunteer for studies, 
how the developed world shares with 
the developing world. It’s changed the 
way we look at treatment—its develop-
ment, its pricing, its evolution, the way 
it’s administered. It’s changed the way 
we think about access to care. … AIDS, 
in short, is a kind of crucible in which 
old protocols and assumptions are 
melted down and remade.”
familiar and less familiar environments. 
For those who are perceptive, it can give 
clues about how society prioritizes or fails 
to prioritize a particular research direction. 
At any one time there is at least one session 
that is purely basic science (see Tidbits 
from Toronto). The rest—the surrounding 
chaos of human contention—may not 
change the experiment that gets done 
tomorrow, but its long-term impact on 
personal motivation and research strategy 
should be profound.
This remaking is one justifi  cation 
for the size of the AIDS industry. Other 
diseases are also important, but it is on 
the back of AIDS interventions that the 
possibilities of healthcare in developing 
countries are being redefi  ned. Surely the 
scientifi  c community should contribute to 
(or at least be aware of) this process?
The AIDS meeting is a place where 
researchers can witness, in one place, the 
winding path from basic discovery through 
clinical research to clinical impact in both 
Tidbits from Toronto
Some talks didn’t necessarily fit into a big global picture, but nevertheless 
included some intriguing science. A few examples are outlined below.
Receptor plus drug = entry
Among the more recent anti-HIV drugs 
are the entry inhibitors, which block 
HIV from using its coreceptor CCR5 
and thus keep the virus outside the 
cell. The viruses that escape from this 
inhibition do so by using a composite 
CCR5-plus-inhibitor complex as a key 
to entry, reported Pavel Pugach (Weill 
Medical College of Cornell University, 
New York, NY). Not just any CCR5 
ligand will do, however. The mutant 
virus can actually be blocked from 
entering by the addition of RANTES, 
which is the usual ligand for CCR5 
but has a different shape than the 
inhibitor drug.
Prevention antibodies
Tanawan Samleerat (Chiang Mai 
University, Thailand; and François 
Rabelais University, Tours, France) 
confirmed that the risk of mother-to-
child transmission is far lower when 
mothers have neutralizing antibodies 
to HIV. This is one more hint that 
antibodies to HIV are not completely 
impotent.
One virus begets another
Infection with Herpes simplex virus 
type 2 (HSV2) is common and is 
associated with a threefold increase 
in HIV susceptibility in women, 
although many never experience 
genital ulceration. Anu Rebbapragada 
(University of Toronto, Canada) 
suggested that other, molecular 
factors may explain the increased 
susceptibility. She found that HSV2-
infected female sex workers had more 
target cells for HIV infection: a 10-
fold increase in DC-SIGN
+ immature 
dendritic cells and a threefold 
increase in CCR5
+ CD4
+ T cells. Thus, 
microbicides that target DC-SIGN and 
CCR5 may be particularly effective.
A proxy for destruction
Human endogenous retrovirus (HERV) 
sequences may help keep immune 
reactions to HIV alive, said Keith 
Garrison (University of California, 
San Francisco, CA). Garrison looked 
at regions of similarity between 
HERV sequences, which make up 
approximately 8% of the human 
genome, and HIV. Early during 
HIV infection, there were immune 
responses to these regions of 
similarity—probably because of 
immune reaction to HIV itself. 
But later there also arose immune 
reactions to the parts of HERV 
sequences that are dissimilar to 
HIV, indicating that the normally 
dormant HERV sequences had been 
reactivated. This is not surprising: 
HIV brings along the vif protein; vif 
inactivates APOBEC3G; and inactivated 
APOBEC3G can no longer suppress 
HERV sequences. The reactivation may 
also be of some use to the host, as it 
marks the cells containing HIV. The HIV 
epitopes mutate to escape immune 
attack, but HIV-infected cells will still 
be marked by invariant HERV peptides. 
If those peptides are truly specific to 
HIV-infected cells, they might make a 
good target for a vaccine.2400  JEM Vol. 203, No. 11, 2006 00 2400 
So many of the academic musings at an AIDS conference have 
life and death implications, and the session on “responsible 
journalism” was no exception. The underlying question, said 
Daniel Kuritzkes (Brigham and Women’s Hospital, Boston, MA), 
was simple: “At what point can scientiﬁ  c controversies be consid-
ered settled?” The context was AIDS denialism—proposals such 
as those by Peter Duesberg (University of California, Berkeley) 
that HIV does not cause AIDS and by the Perth group (www.
theperthgroup.com) that HIV may not even exist. As John Moore 
(Weill Medical College of Cornell University, New York, NY) 
stated: “This is dangerous stuff. AIDS denialism kills.”
All participants agreed on this statement and its under-
lying logic: public doubt about links between HIV and AIDS have 
caused countless people to have unsafe sex, stop taking life-
saving antiretroviral drugs, avoid getting screened for HIV, and 
avoid taking drugs to prevent mother-to-child transmission of 
HIV. The consequences have been the worst in South Africa, 
where HIV prevalence is now 30% among mothers attending 
antenatal clinics, and only approximately one in ﬁ  ve of those 
who need antiretroviral drugs can get them.
In South Africa, President Thabo Mbeki and Health Minister 
Manto Tshabalala-Msimang have been criticized for their very 
public doubts about HIV’s importance 
and the efﬁ   cacy of antiretroviral 
drugs, and the vocal vitamin proponent 
Matthias Rath has loudly declared anti-
retrovirals to be toxic and multivitamins 
to be the correct solution to AIDS. The 
South African NGO Treatment Action 
Campaign (TAC) has led the ﬁ  ght against the government and 
Rath—in Toronto TAC stormed South Africa’s exhibit to protest 
the display of garlic, beetroot, and lemon (a mixture often pro-
moted by the health minister) alongside antiretrovirals.
For the South African journalists on the panel, the question 
was how to cover this story without making things worse. “Does 
balanced reporting mean you give the lunatic fringe equal weight 
Should journalists question science?
Imperfect messengers.  Occupants of the bustling press room at the 
AIDS conference must decide how much to challenge HIV researchers.
or rights—do they have right to reply?” asked Tamar Khan, from 
South Africa’s Business Day. “[With] the AIDS dissidents… we 
don’t cover blow-by-blow every activity they do. We try to be 
selective. But when these people are given an audience by your 
health minister, your readers need to know that.”
The evidence presented by the denialists is ﬂ  imsy, accord-
ing to Moore. They cite old, long-refuted papers, cherry pick 
data, use the evolution of scientiﬁ  c knowledge as evidence of 
errors, claim that acceptance of any research grant 
betrays a fatal bias in favor of the granting agency, 
and claim false afﬁ  liations to institutions that have 
long disowned them.
But the case is made worse by some journalists. 
Cited prominently was a recent Harper’s article, which 
is the latest attack on AIDS researchers by long-time 
activist reporter Celia Farber. The view from South Africa on this 
work was clear. Most at fault are “journalists who think that by 
doing a few hours of research on the Internet they can over-
throw… millions of person-hours of research done by scientists,” 
said Nathan Geffen, policy coordinator at TAC. “That is a failure 
of ethics. That’s an arrogance.”
“Is it really the role of the media to challenge scientiﬁ  c 
consensus?” he continued. “Does the media have the expertise 
to challenge the scientiﬁ  c consensus? In my view, it doesn’t.”
This blanket statement drew a caution from Richard 
Horton, editor-in-chief of the Lancet. “Science is treated as 
truth—that anything that’s published in a journal has to be right,” 
he said. “That’s wrong. We publish stuff that’s wrong every day.” 
Without a critical media, he said, the scientiﬁ  c establishment can 
be let off the hook in a way that no other group ever is.
The last word came from the journalist Laurie Garrett. “A 
lot of science writers do overly rely on the journals and basi-
cally translating things straight from the journals without much 
critical analysis,” she admitted. But she sympathized with 
Geffen’s description of “utter drivel that’s published daily” in 
South Africa. “For us in North America, it’s almost an intellec-
tual debate,” she said. But at the conference “we’re trying to 
globalize this discussion and take it out of the comfortable 
place of Toronto into something larger”—into a place where it 
is a matter of life and death.
Scientists must be 
challenged, but not 
at the expense of 
accepted theories.
Down with Manto.  Activists take the stage during a session on “The Price 
of Inaction” to protest the policies of South Africa’s health minister.
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“An AIDS vaccine is the only tool that 
can end the pandemic,” said Seth 
Berkley, CEO and president of the 
International AIDS Vaccine Initiative 
(IAVI). As Berkley explained, the costs 
for antiretroviral treatment in develop-
ing countries will reach $3–9 billion per 
year for 2007, so a 
gigantic effort to de-
velop a vaccine is cer-
tainly warranted.
The gigantic 
part, at least, is com-
ing to pass. The effort 
is so large that it 
doesn’t even need the 
word “vaccine” to be 
instantly recognized: 
it is called merely 
“The Enterprise.” 
More formally it is the 
Global HIV Vaccine 
Enterprise, which acts 
as an umbrella for 
IAVI, CHAVI (Center 
for HIV/AIDS Vaccine Immunology; 
funded by the NIH), and the CAVD 
(Center for AIDS Vaccine Development; 
funded by the Bill and Melinda Gates 
Foundation). IAVI was founded in 1996 
but its new friends are larger in dollar 
terms: CHAVI grants could total $300 
million over 7 years, and CAVD recently 
announced its 16 grants totaling $287 
million over fi  ve years.
Many observers are worried when 
the Enterprise is talked about in terms 
of simple engineering. But, said CHAVI 
director Barton Haynes, “we’re not a 
Manhattan Project—theirs was a tech-
nical issue. We have to defi  ne the en-
abling technology.” José Esparza, 
senior advisor on HIV Vaccines at the 
Bill & Melinda Gates Foundation, is 
also quick to reassure that more diverse 
lines of research will not be lost. “[The 
Enterprise] does not replace the cre-
ativity of individual investigators but 
tries to complement it,” he said.
Will science be heard?
Money does not guarantee success, 
however. “Up to now, the design of 
vaccine candidates has been mostly 
empirical design without enough scien-
tifi  c rationale,” said Francoise Barré-
Sinoussi (Institut Pasteur, Paris, 
France). The new consortia include 
their fair share of common facilities 
aimed at streamlining the empirical 
testing of vaccines, but 
they also include many 
projects aimed at gener-
ating new ideas. CHAVI 
investigators, in particu-
lar, are putting a great 
deal of effort into under-
standing the initial im-
mune response to HIV. 
“By the time the immune 
response gets going,” 
said Haynes, “there is 
such a reservoir of inte-
grated virus and deple-
tion of central memory 
cells that the battle is 
lost.” He hopes that a 
vaccine that accelerates 
the early immune response might con-
quer the virus before it conquers the 
immune system.
Perhaps the biggest challenge is 
the lack of understanding about what 
kind of immune response is needed. 
“You don’t have people that are infected 
and then cured,” said IAVI’s Berkley. 
“We don’t have that natural model.” 
There is even concern about activating 
the immune system too 
much (see Too much of 
a good thing). In one 
vaccine session a ques-
tioner noted that our 
best example of the 
control of HIV-like vi-
ruses is in certain mon-
key species, but even 
then the result has been a peaceful stale-
mate rather than victory. “How tremen-
dous is the challenge to have [T cells] 
and antibody do something that evo-
lution has not been capable of over 
thousands of years,” he said.
The number of vaccine trials is 
increasing sharply, and some themes 
have emerged. It is probably better to 
present multiple HIV proteins and to 
stimulate both B and T cell responses. 
But vast gaps in the underlying immu-
nology remain. Some of the approaches 
to this that were covered at the confer-
ence are described below. Based on the 
conference proceedings, it appears that 
knowledge about the immune response 
to HIV is still fragmented. Comprehen-
sive surveys of all HLA types, all HIV 
peptides, and a wide range of immune 
responses (B cell, T cell, innate, and all 
their molecular subdivisions) need to be 
systematically correlated with resistance 
to infection, and speed of disease pro-
gression. In facing a question of such 
monumental importance, piecemeal 
studies are tantalizing but not enough.
Models: HEPS, LTNPs, 
and macaques
If we made a successful vaccine, what 
would the winning immune reaction 
look like? Clues about these so-called 
“correlates of protection” come from 
various sources, including animal mod-
els, and people who are either highly 
exposed but persistently seronegative 
(HEPS; e.g., sex workers who have un-
protected sex but remain uninfected) or 
long-term nonprogressors (LTNPs; 
people who are infected with HIV but 
do not succumb to AIDS).
Hope for an HIV vaccine got 
its biggest boost back in 2000 when 
macaques were protected from infection 
by infused antibodies. (The challenge 
virus was SHIV, which is based on 
simian immunodefi  ciency 
virus (SIV) but has the 
Env coat protein from 
HIV.) Ruth Ruprecht 
(Har vard  Medical School, 
Boston, MA) emphasized 
that such primate models 
for immunization protec-
tion must mimic the pro-
cess of human infection as closely as 
possible. She suggested challenging with 
heterologous viruses in repeated low 
doses. But others emphasized that test-
ing everything in monkeys, while useful, 
was not enough. If we base our strategy 
on the results of monkey trials, said 
Kelly MacDonald (University of Toronto, 
Canada), “we could be discarding things 
THE ULTIMATE HOPE
Developing an HIV 
vaccine is all the more 
difficult when we 
understand so little 
about the immune 
response to HIV. 
The general.  A lot of money and 
hopes are riding on the efforts of 
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Too much of a good thing
One of HIV’s tactics is to exhaust the immune system by activating it in 
unproductive ways. “There is so much immune activation,” said Photini 
Kiepiela (University of KwaZulu-Natal, Durban, South Africa). “It’s like the 
immune system is hitting the dart board but not the bulls eye.”
According to Angela Meier (Harvard Medical School, Boston, MA), 
one way that HIV does this is very direct. The ssRNA from HIV acts as a 
ligand for Toll-like receptors (TLRs), she said, leading to activation of 
CD8
+ cells.
This particular pathway need not always be negative, however. 
T. Blake Ball (University of Manitoba, Winnipeg, Canada) reported a study 
using peripheral blood mononuclear cells (PBMCs) from highly exposed per-
sistently seronegative (HEPS) women. These PBMCs respond to TLR stimula-
tion by producing more immunosuppressive IL-10 rather than immune stimu-
latory IFN-γ. The dampening effect of the IL-10 may help the women to 
avoid infection by reducing the target population of activated immune cells.
Negative regulation was also reported by Joseph Barbercheck (Tulane 
National Primate Research Center, Covington, LA). He found that the relative-
ly less pathogenic 
SIV infection in Afri-
can green monkeys 
correlates with a 
maintenance of in-
hibitory T regulatory 
cells, which were de-
pleted during the 
more virulent SIV in-
fection of macaques. 
Not reported was 
the situation in sooty 
mangabey monkeys, 
which show a greatly 
reduced response 
to SIV and a better 
outcome.
The overstimu-
lation of the HIV-
  infected immune sys-
tem can lead to rep-
licative exhaustion. 
Telomerase has 
been shown to restore some of these lost functions to CD8
+ cells, and Calvin 
Harley (Geron Corp., Menlo Park, CA) reported at the conference that 
TAT0002, a drug candidate and telomerase activator, can do the same. The 
drug enhanced cytokine production by CD8
+ cells taken from three HIV-infected 
donors. With telomere restoration, “you may be taking these cells out of a 
DNA damage pathway and helping improve their function,” said Harley.
The issue of overstimulation has attracted attention for years, and there 
have been limited trials with immunosuppressants. The results have been 
equivocal. One HIV-positive delegate did, however, ascribe his lengthy 
good health to his taking low doses of the immunosuppressant prednisone. 
If this is true, said monkey researcher Ruth Ruprecht (Harvard Medical School, 
Boston, MA) with a smile, “then you are like a sooty mangabey.”
Slow down.  Françoise Barré-Sinoussi, codiscoverer of HIV, explains 
the detrimental effects of excessive immune activation.
prematurely. The SIV–macaque is such 
a crummy model.”
So the people are important. One 
of the biggest stories at the 1993 AIDS 
conference in Berlin was about a group 
of female sex workers in the Pumwani 
district of Nairobi, Kenya, who were 
seemingly resistant to HIV infection, de-
spite repeated exposures. Rupert Kaul 
(University of Toronto) outlined the 
fi  ndings that have continued to emerge 
from this and similar cohorts of HEPS 
individuals. HIV resistance of HEPS 
individuals has been correlated with 
mutation of the CCR5 coreceptor, and 
the presence of specifi  c cytotoxic T lym-
phocytes, neutralizing IgA antibodies, 
and genital innate factors such as the 
Trappin proteins. This diversity, he said, 
argues for larger and more rigorous 
studies to uncover all the means by 
which HEPS individuals escape HIV in-
fection. It may then be possible to mimic 
these escape tactics (as was achieved by 
using CCR5 inhibitors) in the suscepti-
ble majority of the population.
Not quite as lucky as the HEPS 
individuals, but still very fortunate, are 
those who are LTNPs. The importance 
of HLA context for LTNPs was ex-
plained by Photini Kiepiela (University 
of KwaZulu-Natal, Durban, South 
Africa). Particular HLA types corre-
lated strongly with either effective or 
ineffective HIV control. The favorable 
HLA types may grab hold of HIV 
peptides that make good targets for the 
immune system. Again, larger studies 
are needed to cover all the combina-
tions of peptides and HLA genotypes.
Decoy responses
The human studies rely on correlations 
to identify possible vaccine targets. But 
targeting HIV epitopes that look good 
based on simple correlations may turn 
out to be harmful, suggested Natasha 
Christie (University of Toronto, Canada). 
She found that HIV may be maintain-
ing epitopes unchanged not because the 
epitopes are needed for replication but 
because they lead the immune system 
down the wrong path.
Epitopes that are targeted by the 
immune system are usually put into one 
of two categories. There are those that 
change to avoid the immune system, SPECIAL REPORT | The Journal of Experimental Medicine  2403
and those that cannot change because 
doing so would make the virus inviable. 
The latter group of epitopes would 
make good targets for a vaccine. But 
when Christie looked at some epitopes 
that do not normally mutate, and delib-
erately mutated them in vitro, she 
found that the resulting viruses were 
perfectly viable.
She suggested a very different ex-
planation: these epitopes may be delib-
erately maintained by HIV because 
they engender detrimental immune re-
sponses. An example would be the phe-
notype seen by Yoav Peretz (McGill 
University, Montreal, Canada) in indi-
viduals with fast-progressing disease. 
These individuals’ immune responses 
were more likely to be to HIV peptides 
that prompt secretion of interferon 
(IFN)-γ alone. Slow progressors, by 
contrast, responded to peptides that 
cause the immune system to make the 
more productive combination of IFN-𝗄 
and interleukin (IL)-2.
Making a better immunogen
The one vaccine candidate that has been 
through phase III effi  cacy trials was the 
unsuccessful VaxGen vaccine. It was 
based on the gp120 surface protein of 
HIV. A better gp120 immunogen can be 
designed by pruning, said Ira Berkower 
(Food and Drug Administration, 
Bethesda, MD). He suggested that the 
key binding sites on gp120 are shielded 
by four protein loops. After he lopped off 
the loops, one such deletion increased 
  antibody binding markedly. Entropy ex-
periments suggested that the benefi  t 
came from a conformational change 
rather than the removal of a steric hin-
drance. “We removed something very 
essential [based on alanine scanning] and 
got back something that binds the CD4 
receptor and binds antibody,” he said. 
The resulting molecule may make a 
much better immunogen than gp120.
Overlapping cycles
Appealing as the rational approach may 
be, “each of the successful vaccines that 
the world has made have been done in 
primarily an empirical way,” said Wayne 
Koff, vice-president for research and 
development at IAVI. That means a lot 
of trial and error. “The challenge is to 
compress this down as absolutely far as 
we possibly can,” says Berkley. Small 
trials in populations with high HIV inci-
dence must be run quickly to get early 
clues to effi  cacy. To support this activity, 
“we need more clinical trial capacity in 
developing countries if we want to accel-
erate research,” said Pontiano Kaleebu 
(Uganda Virus Research Institute, En-
tebbe, Uganda). “We need to conduct 
these trials in parallel.”
Many early phase trials are un-
derway, but the phase III trial data that 
everyone is waiting for will come in 
late 2007 or early 2008. This phase III 
trial is testing a Merck adenovirus vec-
tor carrying HIV gag,  pol, and nef 
genes, and is designed to test the effect 
of cell-mediated immune responses. 
One observer of the fi  eld suggested that 
it would be “a miracle” if the vaccine 
candidates already in trials provided 
any meaningful protection, but other 
participants are putting on a brave 
face. “Either way, positive or negative, 
we’ll learn a lot,” said Haynes. He 
hopes the Merck vaccine will provide 
“a beachhead… of a vaccine that we 
can iteratively improve.”
Whether HIV will succumb to a 
neat trick or to brute force is really 
anyone’s guess. The one thing that we 
know for sure, said UN special envoy 
Stephen Lewis, is that the search for an 
HIV vaccine “is the most important 
quest on the planet.”
Packing them in.  Approximately 24,000 people, from activists to scientists, attend the AIDS conference.